Relationship Between HIV-1 Subtype and ARV Response (RELATES)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Frank Graziano, University of Wisconsin, Madison
ClinicalTrials.gov Identifier:
NCT00585793
First received: December 26, 2007
Last updated: March 9, 2012
Last verified: March 2012

December 26, 2007
March 9, 2012
July 2008
February 2010   (final data collection date for primary outcome measure)
HIV-1 subtype affects response to ARVs [ Time Frame: 3 years ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00585793 on ClinicalTrials.gov Archive Site
Comparison of NNRTI/NRTI combinations to Kaletra/NRTI combinations in Ugandan Children [ Time Frame: 3 years ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Relationship Between HIV-1 Subtype and ARV Response
Study of the Relationship Between HIV-1 Subtype and Antiretroviral (ARV) Response in Ugandan Children

Does subtype of HIV-1 affect the response of ARVs given to Ugandan children

There is a growing demand for treatment and access to antiretroviral (ARV) therapy for HIV infection in resource - poor settings. Of all the HIV-1 subtypes (A, B, C, D, F, G, H, J, K and multiple recombinant viruses), ARV drugs were developed by studying primarily subtype B. This HIV subtype predominates in North America, Western Europe and the rest of the industrialized world. However, worldwide, subtype B makes up a minority (about 10%) of the HIV infected population. In Uganda, HIV-1 subtypes A and D predominate. Although there is some evidence that the ARV's developed against subtype B virus have activity against non-subtype B virus, as the demand grows for ARV's in resource-poor settings, it is not entirely clear whether all non-B subtypes will respond robustly to the current ARV's available. Also, it is unknown if drug failure (in the form of viral resistance) to non-subtype B virus is due to mutations that are similar to those seen in subtype B virus. Without more data in resource-poor countries, it is still too early to tell whether different HIV-1 subtypes will require unique drug treatment or salvage strategies for those who fail initial therapy.

The University of Wisconsin (UW) Health HIV Care Program has been partnering with the Mulago Hospital Pediactirc Infectious Disease Clinic (PIDC) for the past five years. The PIDC has well over 5,000 children with HIV that attend this clinic. Approximately 20% of these children have met criteria for ARV treatment under the US PEPFAR (Presidents Emergency Plan for AIDS Relief) arrangement. A retrospective collaborative (UW/PIDC) study performed at the PIDC examined (using genotyping) 40 children who failed initial ARV therapy. This study found some different mutations in children who failed the antiretroviral therapy.

Based upon the above study, the goal of the present cohort study is to examine prospectively in an expanded population of children who attend the PIDC the relationship between the HIV subtype infecting Ugandan children and their virologic and clinical response to the ARV's now available to this population. Approximately 30% of children are currently failing (based primarily upon clinical data) ARV therapy at the PIDC. In this study, these children will have a separate tube of 5 cc of blood drawn (at specified times) for HIV subtyping to examine whether specific subtypes of HIV are associated with failure to specific ARV's or ARV combinations. In addition to HIV subtype determination, viral genotyping (viral mutations) will be performed to examine the relationship between the HIV subtype and specific viral mutations indicating resistance to an ARV.

The overall design of this study is to prospectively collect cohort clinical and virologic data from children (ages birth to 16 years) started on ARV therapy during a 12 month period of enrollment (about 110 children who qualify for PEPFAR ARV treatment). The only inclusion criteria is the child receives ARV therapy. The only exclusion is refusal on the part of the patient or family to have blood drawn and records examined. Children receiving ARV therapy in this time period will be approached and recruited for this study by the attending physician. This study is approved by the University of Wisconsin Hospital and Clinics and Mulago Hospital IRBs.

All treated children will have clinical and HIV genotype and subtype data (blood sent to U. Wisconsin for analysis) collected prior to starting ARV's. Children will then receive as initial therapy for HIV infection 2 NRTIs (AZT, d4T, ABC or ddI) and 1 NNRTI (Neverapine, or Efavirenz) or Kaletra (a protease inhibitor). One month after starting ARVs (and every four months thereafter during the study period) an HIV viral load will be obtained. If the child is failing therapy, clinical data at the time of failure will be collected and blood will be drawn for repeat viral load, HIV-1 subtyping (has the subtype changed), and genotypic analysis (see below). Decisions on what to use as treatment for those children failing their first antiretroviral regimen will be made using the data collected on the blood obtained from each child in the study.

ARV failure at the PIDC is generally assessed on clinical grounds (weight loss, diarrhea, fever, opportunistic infection [OI] etc). The PIDC has a fairly sophisticated data management system. In those children having clinical failure to the ARV's after initial therapy, blood for HIV-1 viral load, subtype and genotype will be drawn. This blood will be frozen and shipped to the University of Wisconsin for analysis. On site (Dr. Kekitiinwa) clinical data will be collected. This data will include age, sex, physical findings and clinical course on ARV's. More specifically, the reason for ARV failure was: the occurrence of OI, wasting, recurrence of diarrhea, (other symptoms of HIV), or toxicity to the ARV (tolerability). All blood samples will be labeled only with a number that corresponds to the identity of the patient. This number will be kept by Dr. Graziano. These samples will then be Federal Expressed on dry ice to the University of Wisconsin where they will be evaluated for HIV-1 subtype and genotype.

No material inducements for recruitment will be offered and no personnel at the PIDC will receive incentives for recruitment of subjects.

This study is minimal risk to the patient. ARV therapy is standard of care at the PIDC for those infected with HIV and having AIDS.

T-tests of significance and other population cohort analyses will be performed to examine whether there is a correlation between HIV-1 subtype, clinical failure, and the appearance of specific genetic resistant mutants. There is no statistical justification for the sample size.

The only risk from this study is bruising and the transient pain of the blood drawn for analysis (see consent form). Since AIDS is a devastating disease in Uganda and ARV therapy represents the only hope HIV infected children have, there is no particular concern for examination of medical records for these children. There is no cultural sensitivity to drawing blood in PIDC population.

The clinical benefit to the study participants in this research is the knowledge of mutations (in those failing therapy) before starting second line therapy.

Physicians caring for the patient will administer the consent form. All are fluent in English (the national Uganda language) and Lugandan (the prevalent dialect in Kampala and surrounding areas). See the consent form (What your signatures or thumb print means) enclosed for details.

FMG:misc/Study Description.doc

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:

Plasma obtained from participants

Probability Sample

Children $ ,monthe to 16 years

HIV Infections
Drug: NRTI/NNRTI/ Kaletra
Fixed dose and cild formulation Kaletra
PEPFAR 1
Intervention: Drug: NRTI/NNRTI/ Kaletra
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
108
February 2010
February 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • PEPFAR eligible

Exclusion Criteria:

  • OI/sfaety lab abnomalities
Both
4 Months to 16 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Uganda
 
NCT00585793
H-2006-0206
No
Frank Graziano, University of Wisconsin, Madison
University of Wisconsin, Madison
Not Provided
Principal Investigator: Frank M Graziano, MD/PhD UWHC
University of Wisconsin, Madison
March 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP